
This is what a surgical clinic looked like in ancient Rome
Doctor in the house
What caught the attention of archaeologists most was the first of these houses, which had been rebuilt several times over the years. The last reconstruction took place during the second half of the second century A,D., when the main rooms were remodeled to include rich mosaics and paintings and new rooms were added. Archaeologists were able to identify the areas of a typical Roman mansion: the vestibule; the triclinium (where banquets, receptions, and social gatherings were held); several cubicula (rooms usually identified as bedrooms that also served as reading or meeting rooms); and a latrine. They also found remains of a richly decorated upper floor comprising several rooms, including a kitchen.
Heat therapy
Archaeologists believe that this life-size, foot-shaped terra-cotta vessel found in the Surgeon's House was either used as a flask for storing ointments or medicines or for performing therapeutic heat treatments. It is one of only two such objects found in the Roman world.
Ministero Della Cultura. Soprintendenza Archeologia, Belle Arti e Paesaggio per le Province di Ravenna
But what made this particular Roman house so special were the belongings of the person who lived there in the early third century. A spectacular array of some 150 surgical instruments, made of bronze and iron and manufactured between the first and third centuries A.D., were found among the remains. This was clearly the home of a Roman surgeon. The tools, which would once have been stored in cases and boxes, form the most complete set of surgical instruments ever found from the ancient Roman world.
The archaeologists also found mortars that must have been used in the preparation and storing of drugs. The evidence suggests that the house functioned as a private clinic, or taberna medica, of the early third century, containing both study space and a medical consulting room. They dubbed it the Domus del Chirurgo—the Surgeon's House.
(How ancient remedies are changing modern medicine.)
Tools of the trade
These hooks and scalpels were among some 150 instruments found at the Surgeon's House.
Ministero Della Cultura. Soprintendenza Archeologia, Belle Arti e Paesaggio per le Province di Ravenna
One-third of the instruments found in the Surgeon's House were intended for bone surgery. Others were used for operating on hernias, eyes, and tonsils. They range from hooks and scalpels to instruments for specialized interventions, such as cranial trepanations where part of the skull was removed. The latter instrument is of special interest to historians of medicine, as its design conforms with the written description of an object left by the medical writer Galen, who died in the early third century. None of the Rimini instruments were for gynecological use, strengthening the theory that the surgeon learned his trade on the battlefield.
A good man
At the heart of this taberna medica was a room paved with a mosaic depicting the mythical Greek hero Orpheus. In this room archaeologists discovered most of the surgical instruments. They also found medical paraphernalia in the cubiculum next to the Orpheus room and in the entranceway. And it was there, on a wall, that archaeologists found an intriguing graffito. The inscription in Latin read:
Eutyches
homo bonus
hic habitat.
Hic sunt miseri.
This translates as: 'Eutyches, a good man, lives here. Here are the miserable ones.' It seems reasonable to hypothesize that the text was scratched onto the wall by a sick person being treated by a doctor called Eutyches.
Researchers believe that the doctor trained in Greece and Asia Minor where, in addition to gaining medical knowledge, he acquired cultural artifacts that he took with him to his residence in Ariminum. This would explain the presence of objects outside the city's typical trading circles. These include a panel of fish in glass paste thought to be from what is now Turkey, a bronze votive hand associated with the cult of Jupiter Dolichenus, and a statue of Hermarchus, a Greek Epicurean philosopher.
Objects from places outside Rimini's trading circles suggest the surgeon had traveled widely, like this glass-paste panel with three fish. It likely came from what is now Turkey.
Ministero Della Cultura. Soprintendenza Archeologia, Belle Arti e Paesaggio per le Province di Ravenna
The sophisticated surgical instruments found in the house suggest that Eutyches, if that was indeed his name, had specialized in treating trauma wounds and performing surgery. It is therefore likely that he acquired at least part of his training as a military doctor in the camps, and on the battlefields, of the Roman Empire.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Strawberry moon rises behind the Parthenon in Athens
A full moon, known as the strawberry moon, has risen over the Parthenon in Athens, Greece Tuesday night. The spectacle happens every 2 or 3 years when the moon is aligned over the ancient Greek temple, creating a visually stunning scene.
Yahoo
6 hours ago
- Yahoo
Labs reopen to study archaeological treasures
The laboratories used to carry out research on some of the country's most significant heritage sites have reopened after a refit. The Fort Cumberland Laboratories in Portsmouth have been equipped with tools to help understand how artefacts are made and how best to preserve them. The site has been central in projects ranging including the re-excavation of Silbury Hill in Wiltshire and studying human remains found at Hadrian's Wall. Historic England said the site "plays a vital role in telling the stories of England's past". Specialist work has been carried out at Fort Cumberland for the past 75 years. The team has helped conserve artefacts from the 18th Century Dutch warship the Rooswijk off the Kent coast and analysed human remains at Birdoswald Roman Fort Cemetery at Hadrian's Wall in Cumbria. The refit of the laboratories has involved new heating and cooling systems. New equipment includes a scanning electron microscope and energy dispersive spectrometry system (Sem-Eds) for analysing historic materials. It allows for imaging of very small features such as nanocrystals, as well as mapping the chemical composition of a wide range of materials. The system can be used to analyse dental wear in archaeological remains, the causes of bone discolouration, insect remains and historic building materials. Duncan Wilson, chief executive of Historic England, said: "The amazing work of our archaeologists and heritage scientists is helping to uncover the hidden stories that connect us to our distant past. "This new investment in Fort Cumberland's laboratories will enhance our research and conservation work, and improve access to our expertise, equipment and collections, helping more people to enjoy and care for their heritage." You can follow BBC Hampshire & Isle of Wight on Facebook, X (Twitter), or Instagram. Wood carving is 6,000 years old, experts say Last season of excavation starts at Roman fort Historic England
Yahoo
a day ago
- Yahoo
Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial
PolyPid Ltd. (NASDAQ:PYPD) on Monday announced topline results from its pivotal SHIELD II Phase 3 trial of D-PLEX100 to prevent surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The SHIELD II trial is designed to assess the efficacy and safety of D-PLEX100 administered concomitantly with the standard of care (SoC), which includes prophylactic systemic antibiotics, compared to the SoC alone arm in the prevention of post-abdominal-surgery incisional infection in patients undergoing abdominal colorectal surgeries with large incisions. The trial's primary endpoint is measured by the proportion of subjects with a surgical site infection or mortality for any reason within 30 days post-surgery. FDA Pushes Pause On Axsome Fibromyalgia Drug, New Trial Required Patient safety will be monitored for an additional 30 days. The trial will enroll patients in centers in the United States, Europe, and Israel. D-PLEX100, PolyPid's lead product candidate, is designed to provide local, prolonged, and controlled antibacterial activity directly at the surgical site to prevent SSIs. Following the administration of D-PLEX100 into the surgical site, the PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. The trial met the primary efficacy endpoint, with a significantly lower proportion of primary endpoint events among patients who received D-PLEX100 plus SoC (n=405; 10.9%), compared to SoC alone (n=393; 18.1%), representing a 38% reduction (p<0.005). SHIELD II included three key secondary endpoints: The first key secondary endpoint was met, with a 58% reduction in deep and superficial SSI rates among patients who received D-PLEX100 plus SoC (3.8%) compared to those who received SoC alone (9.5%) (p<0.005). The second key secondary endpoint showed statistical significance in favor of D-PLEX100 plus SoC over SoC alone (p<0.005). The third key secondary endpoint was met with a 62% reduction of patients with an ASEPSIS1 score >20 in the D-PLEX100 plus SoC arm compared to the SoC alone arm (p<0.05). The ASEPSIS score is a clinical tool used to assess surgical wound infections objectively. The independent Data Safety Monitoring Board raised no safety concerns in SHIELD II. The company expects to submit a New Drug Application to the U.S. Food and Drug Administration in early 2026, with a Marketing Authorization Application in the E.U. to follow shortly thereafter. Price Action: PYPD stock is trading higher by 12% to $3.66 at last check Monday. Read Next:Photo by ittawit21 via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.